With increasing age at tumor diagnosis in familial cancer: Cancer is limited to fewer organs
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 11
Abstract
Hereditary cancer that has monogenic inheritance affects every tenth patient, on average, who is diagnosed with cancer, and it has been suggested, based on twin studies, that approximately 30% of all cancer patients have a genetic predisposition to developing cancer. In this article, the author posited that familial syndromes become more organ specific with increasing age at tumor presentation to the point that very late in life, only a few organs are affected by tumors. The reason for this could be that the tumor originates from a more differentiated, organ-specific progenitor/stem cell later in life, while the progenitor/stem cell might be involved in organogenesis in different organs earlier in life. Examples are given for skin cancer, colon, endometrial and breast cancer. Patients with familial cancer who present with cancer at an older age have a more organ-restricted disease. This could be because the tumor has a more differentiated progenitor/stem cell origin. Examples are given for families with breast cancer, melanoma, non-melanoma skin cancer, endometrial and colon cancer.
Authors and Affiliations
Olsson H
Keywords
Related Articles
- EP ID EP547259
- DOI 10.14312/2052-4994.2015-21
- Views 70
- Downloads 0
Effect of chronic liver disease using a multivariate analysis of associated risk factors in patients with hepatocellular carcinoma treated with transarterial chemoembolization
Purpose: To evaluate the effect of chronic liver disease (CLD) in a multivariate analysis of associated risk factors in patients with hepatocellular carcinoma (HCC) using transarterial chemoembolization (TACE). Materials...
Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?
Background: Skin rash during treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) has been reported to be predictive for response and survival in patients with advanced non-small cell l...
Combined treatment of gemcitabine with indole-3-carbinol or metformin on drug efficacy in pancreatic cancer cell lines: The role of human equilibrative nucleoside transporters
Pancreatic cancer is one of the most lethal carcinomas in the United States. In accord with the American Cancer Society pancreatic cancer is anticipated to move from the third to the second leading cause of deaths in the...
Characterizing tobacco use in an American cancer center’s catchment area can help direct future research priorities
Purpose: American cancer centers supported by the National Cancer Institute (NCI) must ensure that their research addresses the cancer relevant needs and risks of members of their catchment area. In 2016, the NCI support...
Carboplatin-gemcitabine in the treatment of elderly patients with non-small cell lung cancer: An outcome analysis
Introduction: To compare a novel carboplatin-gemcitabine (CG) schedule with gemcitabine (G) monochemotherapy in elderly patients with advanced NSCLC. Methods: The records of all the consecutive elderly patients referred...